AstraZeneca’s Lynparza tablet (ingredient: olaparib), a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, has become reimbursable for the first- and second-line maintenance therapy in ovarian cancer patients.The anticancer drug shifted its form from capsule to tablet and obtained health
Hanall Biopharma has begun administrating HL161 (ingredient: batoclimab) in phase 3 clinical trials conducted in China for treating myasthenia gravis. Harbour Biomed, Hanall Biopharm’s Chinese partner, is conducting clinical trials in patients with a rare long-term condition that causes muscle weakn
Local developers of Covid-19 vaccines have announced plans to conduct large-scale, late-stage global trials, raising expectations for homegrown Covid-19 vaccines.However, some companies have to overcome several challenges, and it will take some time to commercialize a local Covid-19 vaccine, observe
Daewon Pharmaceutical said that it found TG Fenon (Ingredient: fenofibrate choline) significantly reduces triglyceride levels, reaffirming its safety in phase 4 clinical trial of treating patients with hypertriglyceridemia.The company compared triglyceride reduction between patient groups that recei
Novartis’ CDK4/6 inhibitor Kisqali (ribociclib), combined with letrozole, extended overall survival by more than one year in patients with hormone receptor-positive, human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer.The company released the results of phase 3 MONALEESA-2 tr
The number of patients treated for heart diseases caused by myocardial ischemia sharply grew in Korea over the past five years, significantly increasing medical expenses for their treatment, data showed.According to the National Health Insurance Service, the number of patients with ischemic heart di
JW Creagene said Monday that it would cooperate with Oncoinsight to develop the next-generation anticancer cell therapy called CAR-M.Through this collaboration, the two companies will jointly research and develop a CAR-Macrophage (CAR-M). This anticancer cell therapy combines a chimeric antigen rece
The market competition of combination therapies for hypertension and dyslipidemia is likely to heat up, as Yuhan Corp. and JW Pharmaceutical recently won approval for related products.Prescriptions of dyslipidemia combo drugs jumped 21 percent on-year to 633.5 billion won ($536.7 million) in Korea i
Avastin (bevacizumab), a vascular endothelial growth factor (VEGF) inhibitor, is almost a staple in anticancer treatment combined with chemotherapy or immunotherapy in various types of cancer.After Samsung Bioepis’ biosimilar of Avastin became reimbursable in Korea, the government notified that it w
Homegrown antibody biosimilar products are accelerating their penetration into the global market, as two makers -- Samsung Bioepis and Celltrion – have scored 11 approvals in Europe and eight in the U.S.The achievement came eight years after Celltrion won the nod for Remsima (ingredient: infliximab)
Huons has signed an agreement with AriBio, a biotech firm specializing in medicines for neurodegenerative and infectious disease, to develop new brain disease and dementia drugs targeting the global market.The two partners signed an agreement to develop AriBio's treatment candidates for brain diseas
Yuhan Corp.’s new anti-cancer drug Leclaza (ingredient: lazertinib), in combination with Janssen’s Rybrevant (ingredient: amivantamab), raised the response rate and extended the duration of response in advanced non-small cell lung cancer (NSCLC) patients who failed previous treatment.Researchers pre
Despite the prolonging Covid-19 pandemic, many Korean biopharmaceutical companies took part in the 2021 European Society for Medical Oncology (ESMO) Congress, one of the largest cancer meetings globally, to present their development of pipelines.ESMO presents the latest scientific developments in ba
Access Bio signed an agreement with PharmGen Science and New Jersey’s IVY Pharma to jointly develop a biosimilar of Covid-19 mRNA vaccine as part of the global vaccine partnership between Korea and the U.S.Under the accord, Access Bio and PharmGen Science will co-invest in IVY Pharma’s research on c
Sanofi-Aventis Korea said Thursday that oral biologic Dupixent (ingredient: dupilumab) has reaffirmed its efficacy in improving the quality of life of severe asthma patients by preventing symptom exacerbations.The company presented its study results at a recent online meeting hosted by the European
The government has recently authorized Covid-19 therapy Regkirona, developed by Celltrion, more than a year-and-a-half after the nation recorded the first confirmed case in early 2020.Now the challenge for most drugmakers here is more convenient oral therapy.The Ministry of Food and Drug Safety rece
With the number of pet owners growing and related industries enjoying a boom in Korea, local pharmaceutical companies are starting to advance into the veterinary drug market in earnest.The size of the domestic companion animal-related market grew from 900 billion won ($764.9 million) in 2012 to 5.8
Chinese pharmaceutical companies, armed with new drug technology developed by huge capital, are targeting the local market in earnest.China has been Korea's largest importer of raw materials for pharmaceuticals, but the world’s second-largest economy has rarely exported finished products to Korea un
JW Pharmaceutical said that it has launched Fuenpera, an influenza treatment in an intravenous (IV) injection, and has begun full-scale marketing activities.“Unlike oseltamivir, which patients have to receive orally for five days, Fuenpera uses peramivir hydrate as its main substance that treats the
Bridge Biotherapeutics said that it has presented the preclinical data of BBT-176, a non-small cell lung cancer (NSCLC) treatment, during the 2021 European Society for Medical Oncology (ESMO) Congress.“We have presented the preclinical research data related to the tumor suppression efficacy of BBT-1